Suzuki R, Ihira M, Enomoto Y, Yano H, Maruyama F, Emi N, Asano Y, Yoshikawa T.	Heat denaturation increases the sensitivity of the cytomegalovirus loop-mediated isothermal amplification method.	Microbiol Immunol	54	466-470	2010
Ihira M, Sugiyama H, Enomoto Y, Higashimoto Y, Sugata K, Asano Y, Yoshikawa T.	Direct detection of human herpesvirus 6 DNA in serum by variant specific loop-mediated isothermal amplification in hematopoietic stem cell transplant recipients.	J Virol Methods	167	103-106	2010
Nakamura T, Sato Y, Watanabe D, Ito H, Shimonohara N, Tsuji T, Nakajima N, Suzuki Y, Matsuo K, Nakagawa H, Sata T, Katano H.	Nuclear localization of Merkel cell polyomavirus large T antigen in Merkel cell carcinoma.	Virology	398	273–279	2010
Kanno T, Sato Y, Nakamura T, Sakamoto K, Sata T, Katano H.	Genotypic and clinicopathological characterization of Kaposi's sarcoma-associated herpesvirus infection in Japan.	J Med Virol	82	400-406	2010
Shiota T, Kurane I, Morikawa S, Saijo M.	Long-term observation of HSV-1 infections in a child with Wiskott-Aldrich syndrome and possible mechanism of TK-negative HSV-1 in humans.	Jpn J Infect Dis	64	121-126	2011
Shiota T, Wang L, Ito M, Iizuka I, Ogata M, Tsuji M, Nishimura H, Taniguchi S, Morikawa S, Kurane I, Mizuguchi M, Saijo M.	Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay.	Antiviral Res	91	142-149	2011
Nakamichi K, Kurane I, Saijo M.	Evaluation of a quantitative real-time PCR assay for detection of JC polyomavirus DNA in cerebrospinal fluid without the need for nucleic acid extraction.	Jpn J Infect Dis	64	211-216	2011
Ishibashi K., Tokumoto, T., Tanabe, K., Shirakawa, H., Hashimoto, K., Kushida, N., Yanagida, T., Shishido, K., Aikawa, K., Toma, H., Inoue, N., Yamaguchi, O., Suzutani, T.:	The lack of antibodies against the AD2 epitope of cytomegalovirus (CMV) glycoprotein B (gB) is associated with CMV disease after renal transplantation in recipients having gH serotypes same as their donors.	Transplant Infec Dis	13	318-323	2011
Yamamoto M, Takakura S, Hotta G, Matsumura Y, Matsushima A, Miki N, Ito Y, Ichiyama S.	Clinical characteristics and risk factors of non-Candida Fungaemia in a tertiary-care university hospital in Japan	Eur J Clin Mic	crobiol	Infect Dis (	in

Inoue N.	Chapter 84 Human herpesvirus 5 (cytomegalovirus),	In: (Ed) Liu D,  "Molecular detection of human viral pathogens"  Taylor & Francis CRC Press.	949-962	2011
Nagi M, Nakayama H, Tanabe K, Bard M, Aoyama T, Okano M, Higashi S, Ueno K, Chibana H, Niimi M, Yamagoe S, Umeyama T, Kajiwara S, Ohno H, Miyazaki Y.	Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic genes in Candida glabrata.	Genes Cells 16	80-89	2011
Tomita H, Muroi E, Takenaka M, Nishimoto K, Kakeya H, Ohno H, Miyazaki Y, Utani A.	Rhizomucor variabilis infection in human cutaneous mucomycosis	Clin Exp 36 Dermatol	312–314	2011
Kobayashi T, Kakeya H, Miyazaki T, Izumikawa K, Yanagihara K, Ohno H, Yamamoto Y, Tashiro T, Kohno S.	Synergistic antifungal effect of lactoferrin with azole antifungals against Candida albicans and a proposal for a new treatment method for invasive candidiasis	Jpn J 64 Infect Dis	292-296	2011
Kimura M, Araoka H, Uchida N, Ohno H, Miyazaki Y, Fujii T, Nishida K, Izutsu K, Wake A, Taniguchi S, Yoneyama A.	Cunninghamella bertholletiae pneumonia showing a reversed halo sign on chest computed tomography scan following cord blood transplantation.	Med Mycol (in press 22 Nov 2011. DOI: 10.3109/13693786.2		
Gyotoku H, Izumikawa K, Ikeda H, Takazono T, Morinaga Y, Nakamura S, Imamura Y, Nishino T, Miyazaki T, Kakeya H, Yamamoto Y, Yanagihara K, Yasuoka A, Yaguchi T, Ohno H, Miyzaki Y, Kamei K, Kanda T, Kohno S.	A case of bronchial aspergillosis caused by Aspergillus udagawae and its mycological features.	Med Mycol (in press 13 Dec 2011. DOI: 10.3109/13693786.2		
大野秀明.	中枢神経系真菌感染症における最 近の動向.	最新医学 66	997– 1004	2011
大野秀明.	髄膜炎, 脳炎. 新版 感染症診療実 践ガイド 有効な抗菌薬の使い方の すべて.	Medical Practice 臨 時増刊号(文光 堂, 東京)	352–358	2011
Tomita Y, Yasuda Y, Hyodo H, Koike T, Shimizu T, Morimoto T, Hattori K, Matsumoto M, Inoue H, Yabe H, Yabe M, Shinohara O, Kojima S, Minemura T, Kato S.	High incidence of fatty liver and insulin resistance in long-term adult survivors of childhood stem cell transplant.	Bone 46 Marrow Transplant	416-425	2011

Masuda H, Alev C, Akimaru H, ito R, Shizuno T, Kobori M, Horii M, Ishihara T, Isobe K, Isozaki M, Itoh J, Itoh Y, Okada Y, McIntyre BA, Kato S, Asahra T.	Methodological development of a clonogenic assay to determine progenitor cell potential.	Circ Res	109	20-37	2011
Yabe M, Morimoto T, Shimizu T, Arakawa S, Kato S, Yabe H.	Therapy-related myelodysplastic syndrome of recipient origin in a juvenile myelomonocytic leukemia patient 17 years after allogeneic BMT.	Bone Marrow Transplant	46	1023- 1025	2011
Yabe M, Shimizu T, Morimoto T, Koike T, Takakura H, Suganuma E, Sugiyama N, Kato S, Yabe H.	Alternative donor marrow transplantation in children with aplastic anemia using low-dose irradiation and fludarabine-based conditioning.	Bone Marrow Transplant	46	1148- 1150	2011
Morio T, Atsuta Y, Tomizawa D, Nagamura-Inoue T, Kato K, Ariga T, Kawa K, Koike K, Tauchi H, Kajiwara M, Hara T, Kato S.	Outcome of unrelated umbilical cord blood transplantation in 88 patients with primary immunodeficiency in Japan.	Brit J Haematol	154	363-372	2011
Kato K, Yoshimi A, Ito E, Oki K, Hara J, Nagatoshi Y, Kikuchi A, Kobayashi R, Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato S; for the Japan Cord Blood Bank Network. Cord Blood Transplantation from Unrelated Donors for Children with Acute Lymphoblastic Leukemia in Japan	The Impact of Methotrexate on Clinical Outcomes.	Biol Blood Marrow Transplant	17	1814- 1821	2011
Yahata T, Takanashi T, Muguruma Y, Ibrahim AA, Matsuzawa H, Uno T, Sheng Y, Onizuka M, Ito M, Kato S, Ando K.	Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells.	Blood	118	2941- 2950	2011
Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H, Tsuchida M, Kato S, Kawase T, Morishima Y, Kodera Y; Japan Marrow Donor Program.	Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia.	Blood	118	3186- 3190	2011
Kawaguchi AT, Aokawa J, Yamada Y, Yoshiba F, Kato S, Kametani Y.	Effect of liposome-encapsulated hemoglobin on antigen-presenting cells in mice.	Artif Organs. 10.1111/j.152			

Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, Tamaki H, Inoue T, Soma T, Kai S, Kato S, Ogawa H.	Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study.	Biol Blood Marrow Transplant. Aug 2 [Epub ahead of print]	3.
Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kobayashi N, Fukuda T, Azuma H, Takanashi M, Mori T, Tsuchida M, Kawase T, Kawa K, Kodera Y, Kato S; for the Japan Marrow Donor Program and the Japan Cord Blood Bank Network.	Comparison of Unrelated Cord Blood Transplantation and HLA-Mismatched Unrelated Bone Marrow Transplantation for Adults with Leukemia.	Biol Blood Marrow Transplant. Oct 1 [Epub ahead of print]	8.
Asano T, Kogawa K, Morimoto A, Ishida Y, Suzuki N, Ohga S, Kudo K, Ohta S, Wakiguchi H, Tabuchi K, Kato S, Ishii E.	Hemophagocytic lymphohistiocytosis after hematopoietic stem cell transplantation in children: A nationwide survey in Japan.	Pediatr Blood Cancer. Oct 28. doi: 10.1002/pbc.23384. [Epub ahead of print]	
Koike T, Yanagimachi N, Ishiguro H, Yabe H, Yabe M, Morimoto T, Shimizu T, Takakura H, Kato S.	High Incidence of Radiation-Induced Cavernous Hemangioma in Long-Term Survivors Who Underwent Hematopoietic Stem Cell Transplantation with Radiation Therapy during Childhood or Adolescence.	Biol Blood Marrow Transplant. Dec 2 [Epub ahead of print]	3.
Ishigami M, Kamei H, Nakamura T, Katano Y, Ando H, Kiuchi T, Goto, H.	Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.	J 46 367-377 201 Gastroenterol	11
Gotoh K, Ito Y, Suzuki E, Kaneko K, Kiuchi T, Ando H, Kimura H.	Effectiveness and safety of inactivated influenza vaccination in pediatric liver transplant recipients over three influenza seasons.	Pediatr 15 112-116 201 Transplant	11
Torii Y, Kimura H, Ochi N, Kaneko K, Ando H, Kiuchi T, Ito Y.	Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients	Vaccine 29 4187- 201 4189	11
Ito Y, Kawabe S, Kojima S, Nakamura F, Nishiyama Y, Kaneko K, Kiuchi T, Ando H, Kimura H.	Identification of Epstein-Barr virus-infected CD27+ memory-B cells in liver or stem cell transplant patients.	J Gen Virol 92 2590- 201 2595	11
Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R.	What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma?	Liver 17 S147- 201 Transpl 158	11

Ishigami M, Onishi Y, Ito T, Katano Y, Ito A, Hirooka Y, Kiuchi T, Goto H.	Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients.	Hepatol Res	41	1189– 1198	2011
Hoshino Y, Nishikawa K, Ito Y, Kuzushima K, Kimura H.	Kinetics of Epstein-Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis.	J Clin Virol	50	244-246	2011
Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh K, Kawada J, Fujiwara S, Sugimoto K, Isobe Y, Nishiyama Y, Kimura H.	Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.	Int J Cancer	129	2263- 2273	2011
Ito Y, Kawabe S, Kojima S, Nakamura F, Nishiyama Y, Kaneko K, Kiuchi K, Ando H, Kimura H.	Identification of Epstein-Barr virus-infected CD27 <sup>+</sup> memory B cells in patients after transplantation.	J Gen Virol	92	2590- 2595	2011
Gotoh K, Ito Y, Maruo S, Takada K, Mizuno T, Teranishi M, Nakata S, Nakashima T, Iwata S, Goshima F, Nakamura S, Kimura H.	Replication of Epstein-Barr virus primary infection in human tonsil tissue explants.	PLoS One	6	e25490	2011
Yamamoto H, Kato D, Uchida N, Taniguchi S, et al.	Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia.	Blood	117	3240– 3242	2011
Uchida N, Wake A, Nakano N, Taniguchi S, et al.	Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone.	Transplantat ion	92	366-371	2011
Masuoka K, Uchida N, Ishiwata K, Taniguchi S, et al.	What is the upper age limit for performing allo-SCT? Cord blood transplantation for an 82-year-old patient with AML.	Bone Marrow Transplant	46	619-620	2011
Yoshikawa T, Sugata K, Asano Y, Ihira M, Kumagai T.	Kinetics of the cytokines and chemokines in cases with primary HHV-6 infection.	J Clin Virol	50	65–68	2011
Kawamura Y, Sugata K, Ihira M, Mihara T, Mutoh T, Asano Y, Yoshikawa T	Different characteristics of human herpesvirus 6 encephalitis between primary infection and viral reactivation.	J Clin Virol	51	12-19	2011

Ogata M, Satou T, Kawano R, Yoshikawa T, Ikewaki J, Kohno K, Ando T, Miyazaki Y, Ohtsuka E, Saburi Y, Kikuchi H, Saikawa T, Kadota J.	High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.	J Med Virol	83	702-709	2011
Fukumoto H, Kanno T, Hasegawa H, Katano H.	Pathology of Kaposi's sarcoma-associated herpesvirus infection,	Front Microbiol	2	175	2011
Katano H, Kano M, Nakamura T, Kanno T, Asanuma H, Sata T.	A novel real-time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses.	J Med Virol	83	322-330	2011
Ogawa-Goto K, Ueno T, Oshima K, Yamamoto H, Sasaki J, Fujita K, Sata T, Taniguchi S, Kanda Y, Katano H.	Detection of active human cytomegalovirus by the promyelocytic leukemia body assay in cultures of PBMCs from patients undergoing hematopoietic stem cell transplantation	J Med Virol	84	479-486	2012
Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T.	Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.	Blood 2012 J	an 10.	[Epub ahead	d of
Hyodo H, Ishiguro H, Tomita Y, Takakura H, Koike T, Shimizu T, Morimoto T, Yabe H, Yabe M, Kojima S, Shiraishi K, Minemura T, Kato S.	Decreased serum testosterone levels in long-term adult survivors with fatty liver after childhood stem cell transplant.	Biol Blood Ma		_	2012 Jan
Yamamoto M, Takakura S, Hotta G, Matsumura Y, Matsushima A, Miki N, Ito Y, Ichiyama S.	Clinical characteristics and risk factors of non-Candida Fungaemia in a tertiary-care university hospital in Japan.	Eur J Clin Mi submission)	crobiol	Infect Dis (	in
Nagao M, Saito T, Hotta G, Doi S, Yamamoto M, Matsumura Y, Matsushima A, Ito Y, Takakura S, Ichiyama S.	Clinical characteristics of ocular candidiasis. When should fundoscopy be performed to rule out ocular candidiasis?	Clin Microbio	l Infect	t. (in submis	sion)

Inoue N, Matsushita M, Fukui Y, Yamada S, Tsuda M, Higashi C, Kaneko K, Hasegawa H,	Identification of an antiviral compound that targets the varicella-zoster virus major capsid protein (ORF40) and	投稿中			
Yamaguchi T. 井上直樹,橋本楓,福地早希。	inhibits the normal capsid maturation. 新規抗ヘルペスウイルス薬開発の現 状.	日本臨床(印	7刷中)		
Yamada S, Taniguchi R, Kosugi I, Inoue N	Cytomegalovirus	In: (Eds) Singh "Neuroviral In CRC Press. (	fectior	n" Taylor &	Francis
堀内一宏, 山田萌美, 白井慎 一, 高橋育子, 加納崇裕, 金子 幸弘, 秋沢宏次, 梅山 隆, 宮﨑 義継, 矢部一郎, 佐々木秀直.	脳室内抗真菌薬投与が奏功した Cryptococcus gattii による脳および肺 クリプトコックス症の 1 例.	臨床神経学(	印刷中	).	
Kawakami Y, Oyama N, Sakai E, Nishiyama K, Suzutani T, Yamamoto T.	Childood tinea incognite caused by trichophyton mentagrophytes var. interdigitable mimicking pustular psoriasis.	Pediatr Derma	atol (in	press)	
Sugata K, Taniguchi K, Yui A, Asano Y, Hashimoto S, Ihira M, Yagasaki H, Takahashi Y, Kojima S, Matsumoto K, Kato K, Yoshikawa T.	Analysis of rotavirus antigenemia in hematopoietic stem cell transplant recipients.	Transplant Inf 10.1111/j.1399			
Higashimoto Y, Ohta A, Nishiyama Y, Ihira M, Sugata K, Asano Y, Ablashi DV, Yoshikawa T	Development of human herpesvirus 6 variant specific immunoblotting assay.	J Clin Microbi	ol (in p	ress)	
Tomita Y, Yasuda Y, Hyodo H, Koike T, Shimizu T, Morimoto T, Hattori K, Matsumoto M, Inoue H, Yabe H, Yabe M, Shinohara O, Kojima S, Minemura T, Kato S.	High incidence of fatty liver and insulin resistance in long-term adult survivors of childhood stem cell transplant.	Bone Marrow Transplant	46	416-425	2011
Kawamura Y, Ohashi M, Asahito H, Takahashi Y, Kojima S, Yoshikawa T.	Posterior reversible encephalopathy syndrome in a child with post-transplant HHV-6B encephalitis.	Bone Marrow	Transp	plant (in pre	ss)
Masuda H, Alev C, Akimaru H, Ito R, Shizuno T, Kobori M, Horii M, Ishihara T, Isobe K, Isozaki M, Itoh J, Itoh Y, Okada Y, McIntyre BA, Kato S, Asahra T.	Methodological development of a clonogenic assay to determine progenitor cell potential.	Circ Res	109	20-37	2011
Yabe M, Morimoto T, Shimizu T, Arakawa S, Kato S, Yabe H.	Therapy-related myelodysplastic syndrome of recipient origin in a juvenile myelomonocytic leukemia patient 17 years after allogeneic BMT.	Bone Marrow Transplant	46	1023- 1025	2011

# Ⅳ. そ の 他

### IV. その他

#### 本研究班主催で開催されたシンポジウムの記録

### 平成 21 年度厚生労働科学研究費補助金 新型インフルエンザ等新興・再興感染症研究事業

### 「臓器移植患者の予後および QOL の向上のための真菌やウイルス感染症の 予防・診断・治療に関する研究」

シンポジウム「臓器移植におけるウイルス感染症対策」

- 1 日 時:平成21年11月13日(金)午後3時~午後5時30分
- 2 場 所:国立感染症研究所·戸山庁舎 感染研第一会議室 (東京都新宿区戸山 1-23-1)

### シンポジウムプログラム

- Bone marrow transplantation and viral infections and pathophysiology of viral infections (15:00-15:45)
  - ① Professor Shun-ichi Kato (Tokai University School of Medicine). Hematopoietic stem cell transplantation in Japan: Special emphasis on cord blood transplantation
  - ② Dr. Masayuki Saijo (Department of Virology 1, National Institute of Infectious Diseases). Life-long observation of HSV-1 infections in a child with Wiskott-Aldrich syndrome: lessons learned from a patient
  - ③ Dr. Harutaka Katano (Department of Pathology, National Institute of Infectious Diseases). Pathology of Merkel cell polyomavirus in Japanese cases of Merkel cell carcinoma
- 2. Antiviral agents (16:00-16:45)
  - ① Dr. Naoki Inoue (Department of Virology 1, National Institute of Infectious Diseases). Screening and characterization of chemical compounds that inhibit early phase of CMV and VZV infections.

- Professor Tatsuo Suzutani (Fukushima Medical University). Phenotypic characterization method for HSV and VZV thymidine kinases----canceled
- ③ Dr. Minetaro Arita (Department of Virology 2, National Institute of Infectious Diseases). Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in the viral protein 3A similar to that of enviroxime

### 3. Guest Speaker's presentation

Professor Florence Morfin (Laboratory of Virology, Hospices Civils of Lyon, France, FRE 3011, CNRS / University of Lyon.

Antiviral drugs for herpes simplex virus and adenovirus: activity and resistance features

#### 3 出席者および参加者:

### (研究代表者)

西條政幸 国立感染症研究所 ウイルス第一部第三室室長

#### (研究分担者)

井上直樹 国立感染症研究所 ウイルス第一部第四室室長

片野晴隆 国立感染症研究所 感染病理部 第一室室長

加藤俊一 東海大学医学部 基盤診療学系再生医療科学 教授

谷口修一 国家公務員共済組合連合会 虎の門病院 血液内科 部長

### (研究協力者)

中道一生 国立感染症研究所 ウイルス第一部

後藤希代子 ニッピバイオマトリックス研究所

### (その他)

倉根一郎国立感染症研究所 ウイルス第一部高崎智彦国立感染症研究所 ウイルス第一部林昌宏国立感染症研究所 ウイルス第一部木下一美国立感染症研究所 ウイルス第一部王麗欣国立感染症研究所 ウイルス第一部

塩田智之 国立感染症研究所 ウイルス第一部 飯塚愛恵 国立感染症研究所 ウイルス第一部 加藤みなみ 国立感染症研究所 ウイルス第一部 山田壮一 国立感染症研究所 ウイルス第一部 原田志津子 国立感染症研究所 ウイルス第一部 山口幸恵 国立感染症研究所 ウイルス第一部 国立感染症研究所 ウイルス第一部 大松勉 佐山勇輔 国立感染症研究所 ウイルス第一部 有田峰太郎 国立感染症研究所 ウイルス第二部 鈴木哲朗 国立感染症研究所 ウイルス第二部 森有紀 国家公務員共済組合連合会 虎の門病院 山本久史 国家公務員共済組合連合会 虎の門病院

### シンポジウム発表演題抄録

- "Hematopoietic stem cell transplantation in Japan."
- Special emphasis on cord blood transplantation -

# Shunichi Kato Tokai University School of Medicine

Hematopoietic stem cell transplantation (HSCT) has been increasingly applied to many patients with hematological disorders in many countries. However, stem cell source and donor selection differs between children and adults and varies from country to country. The Center for International Blood and Marrow Transplant Research (CIBMTR) reports worldwide use and outcome of HSCT annually, and 2009 report is as follows; Bone marrow is the primary graft source for transplantation in children, though the use of peripheral blood and umbilical cord blood grafts is increasing. During the period 2003 to 2007, peripheral blood grafts accounted for 28%, and cord blood accounted for 20% of allotransplants in patients younger than 20 years of age. Among adults older than 20 years, peripheral blood is the most common source of allogeneic grafts. The Japan Society for Hematopoietic Cell Transplantation (JSHCT) also reports national use and outcome of HSCT in Japan. BM is also the primary graft source in children and the use of CB is increasing while the use of PB is limited. During the period 2003 to 2007, BM, PB and CB accounted for 68%, 9% and 23% of allo-HSCT in patients younger than 20 years, respectively. Among adults older than 20 years, BM 56%, PB 23% and CB 21% in the

same period. Thus, the proportion of cord blood is higher both in children and in adults in Japan than in other parts of the world.

## Life-long observation of HSV-1 infections in a child with Wiskott-Aldrich syndrome: lessons learned from a patient

Masayuki Saijo. M.D., Ph. D.

Department of Virology 1, National Institute of Infectious Diseases

HSV-1 infections in a child with a congenital immunodeficiency, Wiskott-Aldrich syndrome, were observed over a 10-year period from the primary infection at the age of 3 to the fatal infections at the age of 13. The child was primarily infected with HSV-1 (TAP isolate) at the age of 3, and later suffered from recurrent and intractable mucocutaneous infections. During the course of infections, ACV-resistant and forsarnet-resistant HSV-1 had been recovered. A human leukocyte antigen (HLA)-matched unrelated bone marrow transplantation (BMT) was performed at the age of 13, resulting in severe HSV-1 infections and progressive multifocal leukoencephalopathy. I have closely observed the clinical course of the HSV-1 infections in this patient and learned the important lessons: treatment, diagnosis, and pathophysiology of HSV-1 infections in an immunocompromised patient. In this presentation, I will show some important messages learned from this patient.

### Pathology of Merkel cell polyomavirus in Japanese cases of Merkel cell carcinoma

Harutaka Katano

Department of Pathology, National Institute of Infectious Diseases

Merkel cell carcinoma is a rare malignancy that sometimes occurs in the skin of elderly people. Recently, a new human polyomavirus, Merkel cell polyomavirus (MCV), was identified in Merkel cell carcinoma. MCV DNA was detected in Japanese cases of Merkel cell carcinoma, and we succeeded amplifying a full-length MCV genome from a patient with Kaposi's sarcoma. Immunohistochemistry using a newly developed rabbit polyclonal antibody against large T antigen showed nuclear expression of large T antigen in Merkel cell carcinoma. Nuclear localization may be important for functions of large T antigen. However, many mutations with stop codons have been detected frequently in the large T gene. We identified a nuclear localization signal of large T antigen using deletion mutants. I will show the association of the mutations with nuclear localization in the large T antigen, and the pathogenesis of MCV will be discussed.

Screening and characterization of chemical compounds that inhibit early phase of CMV and VZV infections.

### Naoki Inoue, Ph. D., Department of Virology 1

To simplify the detection of infectious human cytomegalovirus (HCMV) and varicella-zoster virus, we generated cell lines that produced luciferase in a dose-dependent manner upon HCMV and VZV infection, respectively (Wang et al., 2006; Fukui et al., 2008). Using these cell lines, we screened a diverse library of 9,600 compounds and identified several anti-HCMV and anti-VZV compounds. We demonstrated that one of the compounds, 1-(3,5-dichloro-4-pyridyl)piperidine-4- carboxamide (DPPC), was effective against HCMV but not VZV, and that the compound targets the very early phase of CMV infection, probably by disrupting a pathway that is important after viral entry but before immediate-early gene expression. We also analyzed another compound, named 133G4 that inhibited both HCMV and VZV infection. 133G4 inhibited the step of or prior to DNA replication of HCMV and VZV, but not expression of HCMV IE2 and VZV IE62. RT-PCR analyses indicated that expression of HCMV early and late genes was inhibited by 133G4. In transient transfection assay, 133G4 inhibited transactivation function of HCMV IE2 and VZV IE62. DPPC but not 133G4 inhibited growth of murine and guinea pig CMVs. To evaluate antiviral compounds against CMV easily in animal models, we developed an imaging-based evaluation method.

### Phenotypic characterization method for HSV and VZV thymidine kinases

Tatsuo Suzutani, Kazufumi Ikuta, Yasuhiro Ooguchi, Ken Ishioka Department of Microbiology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295

We reported a novel phenotypic characterization method for HSV and VZV thymidine kinases (TK) to screen for acyclovir-resistant virus infection (Suzutani et al. J Clin Microbiol, 2000). This method determines the biochemical phenotype of TK polypeptide, which is synthesized in vitro from viral DNA using a procedure as follow. The TK gene of each sample virus strain is amplified and isolated under the control of a T7 promoter by PCR. The PCR products are transcribed with T7 RNA polymerase and translated in a rabbit reticulocyte lysate. Using this method, enzymatic characteristics and the size of the TK polypeptides encoding HSV and VZV DNA were defined in less than 2 days without virus isolation. The assay should be a powerful tool in monitoring drug-resistant viruses, especially in cases in which virus isolation is difficult.

Endotheliotropic elephant herpesvirus (EIHV-1) was described at 1999 as a novel virus causing fatal hemorrhagic disease of Asian and African elephants in zoo. The virus has not isolated, but partial nucleotide sequence was defined from DNA prepared from infected organs. The DNA sequence data showed the virus codes TK gene in its genome. We plan to study the TK using above methods as co-work with the National Zoo in Washington D.C.

## Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in the viral protein 3A similar to that of enviroxime

Minetaro Arita\*, Takaji Wakita, and Hiroyuki Shimizu

Department of Virology II, National Institute of Infectious Diseases, 4-7-1 Gakuen,

Musashimurayama-shi, Tokyo 208-0011, Japan

Previously, we identified a kinase inhibitor, GW5074, that inhibits poliovirus (PV) and enterovirus 71 (EV71) replication, although its target has remained unknown. To identify the target of GW5074, we searched for cellular kinase inhibitors that have anti-enterovirus activity similar or related to that of GW5074. With this aim, we performed screenings to identify cellular kinase inhibitors that could cooperatively with GW5074 or synthetically in the absence of GW5074. We identified MEK1/2 inhibitors (SL327 and U0126), an EGFR inhibitor (AG1478) and a phosphatidylinositol 3-kinase (PI3K) inhibitor (wortmannin) as compounds with a cooperative inhibitory effect with GW5074, and an Akt1/2 inhibitor (Akt Inhibitor VIII) as a compound with a synthetic inhibitory effect with MEK1/2 inhibitors and AG1478. Individual treatment with identified kinase inhibitors did not affect PV replication significantly, but combined treatment with MEK1/2 inhibitor, AG1478 and Akt1/2 inhibitor suppressed the replication synthetically. The effect of AG1478 in this synthetic inhibition was compensated with other receptor tyrosine kinase inhibitors (IGF-1R Inhibitor II and Flt3 Inhibitor II). We isolated mutants resistance to Flt3 Inhibitor II and GW5074 and found that these mutants had cross-resistance to each treatment. These mutants had a common mutation in viral protein 3A that results in an amino acid change at amino acid position 70 (Ala to Thr), a mutation that was previously identified in mutants resistant to a potent anti-enterovirus compound, enviroxime. These results suggest that some cellular kinase inhibitors and enviroxime have a conserved target in viral protein 3A to suppress enterovirus replication.

### Antiviral drugs for herpes simplex virus, adenovirus and influenza virus: activity and resistance features

Pr Florence MORFIN, PharmD, PhD
Laboratory of Virology, Hospices Civils of Lyon, France
FRE 3011, CNRS / University of Lyon

An overview will be presented about data on antiviral drugs used to treat herpes simplex virus (HSV), adenovirus (AdV) and influenza virus infections.

Antiviral drugs, and acyclovir as a first line, have been largely used to treat HSV infections. Resistance has been detected, mainly in immunocompromised patients. But no increase of resistance incidence could be detected in recent epidemiological studies. Genetic characterization of resistant viruses revealed numerous mutations in the thymidine kinase gene and some could be studied by site-directed mutagenesis.

Regarding AdV infections, they are often very serious especially among bone marrow transplant patients and a recent European survey described risk factors associated with this infection. Two antiviral drugs may be used to treat AdV infections: cidofovir and ribavirin. A large phenotypic study was conducted to evaluate *in vitro* susceptibility of reference strains and clinical isolates belonging to all AdV species. Cidofovir revealed to be active on all seroytpes whereas ribavirin was active on a limited number of species.

Influenza virus infections are more and more often treated by neuraminidase inhibitors, especially in the actual context of influenza pandemic. Resistance to neuraminidase inhibitors has been followed up for a few years, staying at a low level in most studies until 2007-2008 winter were oseltamivir-resistant H1N1 strains became predominant in most countries. A close survey of influenza susceptibility has now to be performed in the context of swine H1N1 pandemic.



Morfin 教授の発表風景



201123009B (7=2716)

平成23年度厚生労働科学研究費補助金/新型インフルエンザ等新興・再興感染症研究事業

# nerpes

臓器移植患者におけるヘルペスウイルス感染症の 診断・治療・予防マニュアル

編集●

臓器移植患者の予後および QOL の向上のための真菌や ウイルス感染症の予防・診断・治療に関する研究班

研究代表者●

国立感染症研究所ウイルス第一部 西條 政幸

臓器移植患者におけるヘルペスウイルス感染症の 診断・治療・予防マニュアル

### 平成 23 年度厚生労働科学研究補助金 新型インフルエンザ等新興・再興感染症研究事業

臓器移植患者の予後および QOL の向上のための真菌やウイルス感染症の予防・診断・治療に関する研究

臓器移植患者におけるヘルペスウイルス感染症の診断・治療・予防マニュアル

平成 21-23 年度 研究組織

研究代表者(班長)

西條政幸

国立感染症研究所・ウイルス第一部長

### 研究分担者

400000000000000000000000000000000000000	
氏名	所属
一山 智	京都大学大学院医学研究科臨床病態検査学・教授
井上直樹	国立感染症研究所ウイルス第一部・第四室長
大野秀明	国立感染症研究所生物活性部,室長
片野晴隆	国立感染症研究所感染病理部 · 室長
加藤俊一	東海大学医学部造血幹細胞移植 · 教授
木内哲也	名古屋大学医学部移植外科学·教授
木村 宏	名古屋大学大学院医学系研究科分子総合医学専攻(微生物・
	免疫学講座ウイルス学分野ウイルス学)・准教授
錫谷達夫	福島県立医科大学微生物学・教授
谷口修一	国家公務員共済組合連合会 虎の門病院血液内科・部長
森 康子	神戸大学大学院医学研究科臨床ウイルス学・教授
吉川哲史	藤田保健衛生大学医学部小児科学・教授

1.	序言····································
2.	臓器移植患者におけるヘルペスウイルス感染症・・・・・・・・・・・・3 錫谷 達夫
3.	単純ヘルペスウイルス・・・・・・・15 西條 政幸
4.	水痘·帯状疱疹ウイルス・・・・・・・・・・・・・・・・・・・・・25 森 康子
5.	サイトメガロウイルス・・・・・・・・・・・・・・・・・・・・29 井上 直樹
6.	EB ウイルス・・・・・・・・・・・・・・・・・・・・・・・39 木村 宏·木内 哲也
7.	ヒトヘルペスウイルス 6・・・・・・・・・・・・・・・・・・・・・・47 吉川 哲史
8.	抗ヘルペスウイルス薬とその使い方・・・・・・・・・・・・・57 井上 直樹
9.	臓器移植患者における感染予防 ・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
10.	臓器移植患者における感染病理学的診断・・・・・・・・・・・・・・・・・・73 片野 晴隆